2017
DOI: 10.1016/j.jaci.2016.08.017
|View full text |Cite
|
Sign up to set email alerts
|

Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults

Abstract: Peanut EPIT administration was safe and associated with a modest treatment response after 52 weeks, with the highest responses among younger children. This, when coupled with a high adherence and retention rate and significant changes in immune pathways, supports further investigation of this novel therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
239
0
4

Year Published

2017
2017
2021
2021

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 274 publications
(246 citation statements)
references
References 36 publications
(57 reference statements)
3
239
0
4
Order By: Relevance
“…In two multi-center trials conducted through CoFAR, we performed short-term stimulation of PBMCs with allergen for 6 or 18h, followed by flow cytometric identification of allergen-responsive T cells through detection of upregulation of the activation marker CD154 (CD40L). In samples analyzed as part of the primary analysis for one trial (Jones et al, 2017), we observed an overall failure rate of 31% in our regulatory T cell panel. Assay failure was due to low event count during acquisition, and these samples were characterized by altered scatter properties, and a low frequency of CD3 + CD4 + T cells.…”
Section: Introductionmentioning
confidence: 95%
“…In two multi-center trials conducted through CoFAR, we performed short-term stimulation of PBMCs with allergen for 6 or 18h, followed by flow cytometric identification of allergen-responsive T cells through detection of upregulation of the activation marker CD154 (CD40L). In samples analyzed as part of the primary analysis for one trial (Jones et al, 2017), we observed an overall failure rate of 31% in our regulatory T cell panel. Assay failure was due to low event count during acquisition, and these samples were characterized by altered scatter properties, and a low frequency of CD3 + CD4 + T cells.…”
Section: Introductionmentioning
confidence: 95%
“…The epicutaneous delivery of protein for immunotherapy is under investigation in patients with cow’s milk and peanut allergies [5053, 54••]. The epicutaneous delivery system solubilizes the allergen by perspiration and disseminates it into the thickness of the stratum corneum [55].…”
Section: Potential Food Allergy Treatmentsmentioning
confidence: 99%
“…Epicutaneous delivery is non-invasive and may pose a lower risk for systemic reactions than other food allergen delivery approaches under study. Preliminary reports suggest that the epicutaneous antigen delivery for food allergy immunotherapy can lead to desensitization and appears to be more effective in children 6 to 11 years old than in older children and adults [53, 54••]. One important difference between the epicutaneous protocol and oral or sublingual approaches is that there is no dose escalation phase: the initial dose is the maintenance dose.…”
Section: Potential Food Allergy Treatmentsmentioning
confidence: 99%
See 1 more Smart Citation
“…These are immune-competent antigen-presenting cells that have the ability to initiate a regulatory T-cell response and communicate with regional lymph nodes. Daily application of EPIT patches containing 250 μg of peanut for 12 months in patients with peanut allergy has been shown to significantly raise the threshold dose for allergic reactions on food challenge [146,147]. The desensitization effect is not as marked as that of OIT, but the rate of adverse effects is minimal and mainly limited to local skin irritation where the EPIT patch has been applied [143].…”
Section: Food Allergen Immunotherapymentioning
confidence: 99%